Inhibition of plasminogen activator inhibitor-1 restores skeletal muscle regeneration in untreated type 1 diabetic mice

Diabetes

Volumn 60, Issue 7, 2011, Pages 1964-1972

  Krause, Matthew P ^a,b   Moradi, Jasmin ^a,b   Nissar, Aliyah A ^a,b   Riddell, Michael C ^b   Hawke, Thomas J ^a,b  

^a MCMASTER UNIVERSITY   (Canada)

^b YORK UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

FATTY ACID; GLUCOSE; INSULIN; MYOGENIN; PLASMINOGEN ACTIVATOR INHIBITOR 1; TIPLASININ; INDOLEACETIC ACID DERIVATIVE; UROKINASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; FATTY ACID BLOOD LEVEL; GLUCOSE BLOOD LEVEL; INSULIN BLOOD LEVEL; INSULIN DEPENDENT DIABETES MELLITUS; MALE; MOUSE; MUSCLE MASS; MUSCLE REGENERATION; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SKELETAL MUSCLE; ANIMAL; DRUG EFFECT; METABOLISM; PATHOPHYSIOLOGY; PHYSIOLOGY; REGENERATION;

ANIMALS; DIABETES MELLITUS, TYPE 1; INDOLEACETIC ACIDS; MALE; MICE; MUSCLE, SKELETAL; PLASMINOGEN ACTIVATOR INHIBITOR 1; REGENERATION; UROKINASE-TYPE PLASMINOGEN ACTIVATOR;

EID: 80052095203     PISSN: 00121797     EISSN: 1939327X     Source Type: Journal    
DOI: 10.2337/db11-0007     Document Type: Article

References (50)

1. Mozdziak PE, Pulvermacher PM, Schultz E. Unloading of juvenile muscle results in a reduced muscle size 9 wk after reloading. J Appl Physiol 2000;88:158-164
2. Wanek LJ, Snow MH. Activity-induced fiber regeneration in rat soleus muscle. Anat Rec 2000;258:176-185
3. Darr KC, Schultz E. Hindlimb suspension suppresses muscle growth and satellite cell proliferation. J Appl Physiol 1989;67:1827-1834
4. Zeitler P, Thiede A, Müller HL. Prospective study on plasma clotting parameters in diabetic children - no evidence for specific changes in coagulation system. Exp Clin Endocrinol Diabetes 2001;109:146-150
5. 13C]leucine. Diabetologia 1990;33:43-51
6. Charlton MR, Balagopal P, Nair KS. Skeletal muscle myosin heavy chain synthesis in type 1 diabetes. Diabetes 1997;46:1336-1340
7. Godil MA, Wilson TA, Garlick PJ, McNurlan MA. Effect of insulin with concurrent amino acid infusion on protein metabolism in rapidly growing pubertal children with type 1 diabetes. Pediatr Res 2005;58:229-234
8. Nair KS, Ford GC, Ekberg K, Fernqvist-Forbes E, Wahren J. Protein dynamics in whole body and in splanchnic and leg tissues in type I diabetic patients. J Clin Invest 1995;95:2926-2937
9. Fricke O, Seewi O, Semler O, Tutlewski B, Stabrey A, Schoenau E. The influence of auxology and long-term glycemic control on muscle function in children and adolescents with type 1 diabetes mellitus. J Musculoskelet Neuronal Interact 2008;8:188-195
10. Jakobsen J, Reske-Nielsen E. Diffuse muscle fiber atrophy in newly diagnosed diabetes. Clin Neuropathol 1986;5:73-77
11. Gordon CS, Serino AS, Krause MP, et al. Impaired growth and force production in skeletal muscles of young partially pancreatectomized rats: a model of adolescent type 1 diabetic myopathy? PLoS ONE 2010;5:e14032
12. Krause MP, Riddell MC, Gordon CS, Imam SA, Cafarelli E, Hawke TJ. Diabetic myopathy differs between Ins2Akita+/- and streptozotocin-induced type 1 diabetic models. J Appl Physiol 2009;106:1650-1659
13. Krause MP, Riddell MC, Hawke TJ. Effects of type 1 diabetes mellitus on skeletal muscle: clinical observations and physiological mechanisms. Pediatr Diabetes. 22 September 2010 [Epub ahead of print]
14. Hawke TJ, Garry DJ. Myogenic satellite cells: physiology to molecular biology. J Appl Physiol 2001;91:534-551
15. Gulati AK, Swamy MS. Regeneration of skeletal muscle in streptozotocininduced diabetic rats. Anat Rec 1991;229:298-304
16. Jerković R, Bosnar A, Jurisić-Erzen D, et al. The effects of long-term experimental diabetes mellitus type I on skeletal muscle regeneration capacity. Coll Antropol 2009;33:1115-1119
17. Vignaud A, Ramond F, Hourdé C, Keller A, Butler-Browne G, Ferry A. Diabetes provides an unfavorable environment for muscle mass and function after muscle injury in mice. Pathobiology 2007;74:291-300
18. Nicholas SB, Aguiniga E, Ren Y, et al. Plasminogen activator inhibitor-1 deficiency retards diabetic nephropathy. Kidney Int 2005;67:1297-1307
19. Lyon CJ, Hsueh WA. Effect of plasminogen activator inhibitor-1 in diabetes mellitus and cardiovascular disease. Am J Med 2003;115(Suppl. 8A):62S-68S
20. Goldberg RB. Cytokine and cytokine-like inflammation markers, endothelial dysfunction, and imbalanced coagulation in development of diabetes and its complications. J Clin Endocrinol Metab 2009;94:3171-3182
21. Fibbi G, D'Alessio S, Pucci M, Cerletti M, Del Rosso M. Growth factordependent proliferation and invasion of muscle satellite cells require the cell-associated fibrinolytic system. Biol Chem 2002;383:127-136
22. Koh TJ, Bryer SC, Pucci AM, Sisson TH. Mice deficient in plasminogen activator inhibitor-1 have improved skeletal muscle regeneration. Am J Physiol Cell Physiol 2005;289:C217-C223
23. Naderi J, Bernreuther C, Grabinski N, et al. Plasminogen activator inhibitor type 1 up-regulation is associated with skeletal muscle atrophy and associated fibrosis. Am J Pathol 2009;175:763-771
24. Suelves M, Vidal B, Ruiz V, et al. The plasminogen activation system in skeletal muscle regeneration: antagonistic roles of urokinase-type plasminogen activator (uPA) and its inhibitor (PAI-1). Front Biosci 2005;10:2978-2985
25. Sisson TH, Nguyen MH, Yu B, Novak ML, Simon RH, Koh TJ. Urokinasetype plasminogen activator increases hepatocyte growth factor activity required for skeletal muscle regeneration. Blood 2009;114:5052-5061
26. Yoshioka M, Kayo T, Ikeda T, Koizumi A. A novel locus, Mody4, distal to D7Mit189 on chromosome 7 determines early-onset NIDDM in nonobese C57BL/6 (Akita) mutant mice. Diabetes 1997;46:887-894
27. Johnston AP, Campbell JE, Found JG, Riddell MC, Hawke TJ. Streptozotocin induces G2 arrest in skeletal muscle myoblasts and impairs muscle growth in vivo. Am J Physiol Cell Physiol 2007;292:C1033-C1040
28. Hawke TJ, Atkinson DJ, Kanatous SB, Van der Ven PF, Goetsch SC, Garry DJ. Xin, an actin binding protein, is expressed within muscle satellite cells and newly regenerated skeletal muscle fibers. Am J Physiol Cell Physiol 2007;293:C1636-C1644
29. Elokdah H, Abou-Gharbia M, Hennan JK, et al. Tiplaxtinin, a novel, orally efficacious inhibitor of plasminogen activator inhibitor-1: design, synthesis, and preclinical characterization. J Med Chem 2004;47:3491-3494
30. Oishi K, Ohkura N, Kasamatsu M, et al. Tissue-specific augmentation of circadian PAI-1 expression in mice with streptozotocin-induced diabetes. Thromb Res 2004;114:129-135
31. Crandall DL, Elokdah H, Di L, Hennan JK, Gorlatova NV, Lawrence DA. Characterization and comparative evaluation of a structurally unique PAI-1 inhibitor exhibiting oral in-vivo efficacy. J Thromb Haemost 2004;2:1422-1428
32. Krause MP, Liu Y, Vu V, et al. Adiponectin is expressed by skeletal muscle fibers and influences muscle phenotype and function. Am J Physiol Cell Physiol 2008;295:C203-C212
33. Hong EG, Jung DY, Ko HJ, et al. Nonobese, insulin-deficient Ins2Akita mice develop type 2 diabetes phenotypes including insulin resistance and cardiac remodeling. Am J Physiol Endocrinol Metab 2007;293:E1687-E1696
34. Andreassen CS, Jakobsen J, Ringgaard S, Ejskjaer N, Andersen H. Accelerated atrophy of lower leg and foot muscles - a follow-up study of longterm diabetic polyneuropathy using magnetic resonance imaging (MRI). Diabetologia 2009;52:1182-1191
35. Le Grand F, Rudnicki MA. Skeletal muscle satellite cells and adult myogenesis. Curr Opin Cell Biol 2007;19:628-633
36. Smith CK 2nd, Janney MJ, Allen RE. Temporal expression of myogenic regulatory genes during activation, proliferation, and differentiation of rat skeletal muscle satellite cells. J Cell Physiol 1994;159:379-385
37. d'Albis A, Couteaux R, Janmot C, Roulet A, Mira JC. Regeneration after cardiotoxin injury of innervated and denervated slow and fast muscles of mammals. Myosin isoform analysis. Eur J Biochem 1988;174:103-110
38. Schiaffino S, Gorza L, Sartore S, Saggin L, Carli M. Embryonic myosin heavy chain as a differentiation marker of developing human skeletal muscle and rhabdomyosarcoma. A monoclonal antibody study. Exp Cell Res 1986;163:211-220
39. Zimowska M, Brzoska E, Swierczynska M, Streminska W, Moraczewski J. Distinct patterns of MMP-9 and MMP-2 activity in slow and fast twitch skeletal muscle regeneration in vivo. Int J Dev Biol 2008;52:307-314
40. Kherif S, Lafuma C, Dehaupas M, et al. Expression of matrix metalloproteinases 2 and 9 in regenerating skeletal muscle: a study in experimentally injured and mdx muscles. Dev Biol 1999;205:158-170
41. Shortreed KE, Krause MP, Huang JH, et al. Muscle-specific adaptations, impaired oxidative capacity and maintenance of contractile function characterize diet-induced obese mouse skeletal muscle. PLoS ONE 2009;4:e7293
42. Srikanthan P, Hevener AL, Karlamangla AS. Sarcopenia exacerbates obesityassociated insulin resistance and dysglycemia: findings from the National Health and Nutrition Examination Survey III. PLoS ONE 2010;5:e10805
43. Diabetes Control and Complications Trial Research Group. Effect of intensive diabetes treatment on the development and progression of long-term complications in adolescents with insulin-dependent diabetes mellitus: Diabetes Control and Complications Trial. J Pediatr 1994;125:177-188
44. Lluís F, Roma J, Suelves M, et al. Urokinase-dependent plasminogen activation is required for efficient skeletal muscle regeneration in vivo. Blood 2001;97:1703-1711
45. Abderrahmani R, François A, Buard V, et al. Effects of pharmacological inhibition and genetic deficiency of plasminogen activator inhibitor-1 in radiation-induced intestinal injury. Int J Radiat Oncol Biol Phys 2009;74:942-948
46. Weisberg AD, Albornoz F, Griffin JP, et al. Pharmacological inhibition and genetic deficiency of plasminogen activator inhibitor-1 attenuates angiotensin II/salt-induced aortic remodeling. Arterioscler Thromb Vasc Biol 2005;25:365-371
47. Collins SJ, Alexander SL, Lopez-Guisa JM, et al. Plasminogen activator inhibitor-1 deficiency has renal benefits but some adverse systemic consequences in diabetic mice. Nephron Exp Nephrol 2006;104:e23-e34
48. Lassila M, Fukami K, Jandeleit-Dahm K, et al. Plasminogen activator inhibitor-1 production is pathogenetic in experimental murine diabetic renal disease. Diabetologia 2007;50:1315-1326
49. Gogitidze Joy N, Hedrington MS, Briscoe VJ, Tate DB, Ertl AC, Davis SN. Effects of acute hypoglycemia on inflammatory and pro-atherothrombotic biomarkers in individuals with type 1 diabetes and healthy individuals. Diabetes Care 2010;33:1529-1535
50. Small M, Kluft C, MacCuish AC, Lowe GD. Tissue plasminogen activator inhibition in diabetes mellitus. Diabetes Care 1989;12:655-658